Related Experiment Video

Updated: Jul 2, 2026

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter

M Ahn1, S-J Lee, X Li

  • 1Department of Urology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

Cancer Gene Therapy
|September 6, 2008
PubMed

Insights

This study introduces AdIU1, a novel gene therapy for prostate cancer. AdIU1 effectively targets and inhibits androgen-independent prostate cancer cells, showing significant therapeutic potential in preclinical models.

Area of Science:

  • Oncology
  • Gene Therapy
  • Virology

Background:

  • Enzyme pro-drug suicide gene therapy faces challenges with viral delivery and gene transduction efficiency.
  • Previous trials demonstrated safety and proof of principle for tissue-specific promoter-based thymidine kinase (TK)/pro-drug therapy in prostate cancer metastases.

Purpose of the Study:

  • To evaluate the efficacy of AdIU1, a prostate-restricted replicative adenovirus (PRRA) encoding herpes simplex virus thymidine kinase (HSV-TK), against androgen-independent (AI), PSA/PSMA-positive prostate cancer cells.
  • To assess the therapeutic potential of AdIU1 combined with ganciclovir (GCV) in preclinical models.

Main Methods:

  • Development of AdIU1, a PRRA carrying the HSV-TK gene.
  • In vitro assessment of AdIU1 plus GCV on AI prostate cancer cell lines (CWR22rv, C4-2) expressing PSA/PSMA, compared to a negative control (DU-145).
  • In vivo evaluation of AdIU1 plus GCV efficacy against CWR22rv tumors in nude mice.

Main Results:

  • AdIU1 plus GCV significantly inhibited the viability of AI, PSA/PSMA-expressing prostate cancer cells in vitro.
  • Cytotoxicity was specific to PSA/PSMA-positive cell lines, with no effect on PSA/PSMA-negative cells.
  • AdIU1 plus GCV demonstrated a superior therapeutic effect against established tumors in vivo compared to AdIU1 or AdE4PSESE1a alone or with GCV.

Conclusions:

  • AdIU1 combined with GCV shows significant therapeutic potential for treating androgen-independent, PSA/PSMA-positive prostate cancer.
  • This approach offers a promising strategy for specific oncolysis and suicide gene therapy in advanced prostate cancer.
  • The findings support further development of AdIU1 for prostate cancer gene therapy.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.